- Solianis Monitoring AG presents its Non-Invasive,
Continuous Glucose Monitoring System at the 3rd International
Conference on Advanced Technologies and Treatments for Diabetes
(Basel, Switzerland, February 10-13, 2010).
Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis,
will present the concept of Solianis' proprietary Multisensor
Glucose Monitoring System (MGMS) which in first tests under daily use
conditions performed according expectations.
"We are pleased with this progress" says Mario Stark, CEO of
Solianis. "Currently we are setting up manufacturing and will
subject our final prototype to rigorous clinical tests. These
tests are the prerequisite to obtain CE approval for market entry in
Europe in 2011. They will also give us the assurance that our MGMS is
safe and provides people with diabetes with the information they and
their healthcare professionals need. As an organization, we are
expanding from a start-up enterprise towards a company which takes
the responsibility to bring a reliable MGMS to market. Our ongoing
interaction with scientific and clinical experts as well as patient
groups ensures that MGMS becomes a system that meets the day-to-day
needs of people with diabetes, their relatives and healthcare
Solianis Monitoring AG is a Swiss medical device company
developing an innovative non-invasive Continuous Glucose
Monitoring (CGM) system for people with diabetes, their relatives and
health care professionals. Its unique and proprietary technology is
integrated in a Multisensor Glucose Monitoring System (MGMS) which
continuously delivers information on glucose variations comparable to
the minimally invasive devices currently approved by the FDA.
Solianis was incorporated in May 2005 and has so far been funded
by private investors, the Pioneer Fond of the Zurich Cantonal
Bank and the EGS Beteiligungen AG. Solianis plans to introduce
its first product for insulin dependent patients with diabetes in
Europe in 2011, after product registration.
ots Originaltext: Solianis Monitoring AG